Skip to main content
padlock icon - secure page this page is secure

Open Access Digoxin and Heart Failure: Are We Clear Yet?

Download Article:
(HTML 89.1 kb)
(PDF 395.4 kb)
The Digoxin Investigation Group trial has multiple flaws in the trial design for the findings to be universally applicable. Digoxin in low serum concentrations (0.5‐0.9 ng/mL) has been shown to decrease mortality in heart failure patients. Multiple trials in different patient populations also show benefit of digoxin in heart failure patients, including women, elderly patients, renal disease patients, and patients with heart failure with preserved ejection fraction. Retrospective observational data linking digoxin use for treatment of atrial fibrillation to increased mortality is not seen in subgroups of randomized controlled trials or population registries. Digoxin remains a useful drug in the toolbox of physicians dealing with heart failure patients.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: digoxin; digoxin toxicity; heart failure; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction

Document Type: Research Article

Publication date: May 1, 2017

This article was made available online on January 13, 2017 as a Fast Track article with title: "Digoxin and Heart Failure: Are We Clear Yet?".

More about this publication?
  • Cardiovascular Innovations and Applications (CVIA) publishes focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability in order to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification. Cardiovascular Innovations and Applications is the official journal of the Great Wall International Congress of Cardiology (GW-ICC). It aims to continue the work of the GW-ICC by providing a global scientific communication platform for cardiologists that bridges East and West.

  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Membership Information
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more